Overview

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.

Phase:

Phase 3

Details

Lead Sponsor:

FORUM Pharmaceuticals Inc

Collaborators:

INC Research
Syneos Health

Treatments:

Antipsychotic Agents
Nicotinic Agonists